Fifty percent recruitment milestone for PROPELLER prostate cancer trial
- Written by PR Newswire
 |
SYDNEY, Dec. 1, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that 15 of 30 participants have been recruited in the diagnostic 64Cu SAR-bisPSMA clinical trial (PROPELLER) in...
